RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update
November 23, 2021 17:25 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Partners with St. Baldrick’s Foundation to Research and Develop New Treatments for Childhood Bone Cancer
November 16, 2021 08:30 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference
November 11, 2021 09:20 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 11, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference
October 21, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
October 12, 2021 10:47 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Receives Notice of Allowance for New U.S. Patent Covering kt-2000 series PARP Inhibitors
October 07, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Oct. 07, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSX-V: RKV) today announced that the Company has received notice of allowance from the...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presents Preclinical Data on novel kt-3000 Series Drug Candidates at JCA-AACR Precision Medicine International Conference
September 16, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present at the JCA-AACR Precision Medicine International Conference
September 09, 2021 12:49 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) ("the Company"), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
August 26, 2021 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing new cancer therapies based on novel...